跳至主要内容
临床试验/NCT01890018
NCT01890018已完成不适用

Partners and Alerts: A Study of Social Forces in Medication Adherence

University of Pennsylvania2 个研究点 分布在 1 个国家目标入组 178 人开始时间: 2013年6月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
178
试验地点
2
主要终点
Glowcap bottle openings/Medication Adherence

研究概览

简要总结

The overall objectives of this study are to improve medication adherence of patients and subsequent health outcomes.

This study is designed to examine the existence of strong associations between social networks and health behavior. This study intends to demonstrate that social forces are particularly effective at building enduring habits for healthy behavior, specifically adherence to statin medication for this study. The investigators believe the improved medication adherence will result in fewer additional vascular events, following the most recent of these events, and will result in fewer patient hospitalizations. The investigators will leverage insights from the fields of social comparison (being provided with information about the actions of others prompts social comparison that can significantly influence behavior), social pressures (encouragement or discouragement from others is a powerful social force that can influence individual behavior), and social triggers (cues in the environment can motivate people to take certain actions and have powerful effects on purchasing behavior).

The results of this study and experience gained from the implementation of these interventions will be used to inform new versions of a larger trial intervention to be tested in new patient cohorts in a rapid cycle framework.

详细描述

This study is a 4-arm pilot study involving 248 patients (62 per arm) who are on a once-a-day statin who have a medication adherence ratio (MPR) that is less than 80%. Patients in all arms would receive a GlowCap, manufactured by Vitality Inc., which records pill-bottle openings and be asked to use the GlowCap for that medication for the duration of the study.

The study arms leverage two strategies that the investigators think will be particularly effective at improving adherence and may be even more effective when used in tandem. Patients in some arms will be asked to select an adherence partner: another person who can help them adhere to their medication regimen. The investigators will contact this adherence partner and ask them to officially accept this role and provide guidance of their choosing as to how they can help the patient adhere. In addition, patients in some arms will receive an alert whenever two full days pass without their GlowCap being opened (i.e. 48 hours of non-adherence). This alert will encourage them to begin taking their medication again. The design allows for some patients to have both an adherence partner and to receive alerts after 48 hours of non-adherence. In these arms, the adherence partner would also receive the alert after 48 hours of non-adherence. This introduces a two-by-two design.

Subjects would spend 6 months in their randomly assigned treatment, and the investigators will compare adherence of subjects in each of the arms to one another.

The investigators plan to track daily adherence of patients to a prescribed chronic disease drug using a new technology that electronically monitors when a pill bottle has been opened. In our control condition, patients will be monitored but not be provided with any reminders, adherence information, or inclusion of friend of family member to help them adhere to their medication. Our four additional treatments will either: (1) email the patient after 48 hours of non-adherence; (2) allow the patient to select friend or family member to encourage medication adherence; (3) email the patient, as well as patient-selected friends or family members after 48 hours of non-adherence; or (4) provide the patient with a daily email, text message, or phone call reminder to take the pill.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Health Services Research
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must have
  • experienced an AMI and have been placed on a once-a-day statin and have a medication adherence ratio (MPR) that is less than 80%.
  • access to internet to create an account on Way to Heath.

排除标准

  • There are no exclusion criterial for patients able to provide consent and who meet the eligibility criteria

研究组 & 干预措施

Control

Active Comparator

This arm will use GlowCaps to have their adherence tracked with no additional modifications:

Arm 1. Control group no modifications

Electronic Pill Bottle tracking

干预措施: Electronic Pill Bottle tracking (Behavioral)

Feedback group

Experimental

This arm will use GlowCaps to have their adherence tracked with the following modifications:

Arm 2. Feedback group participants will receive an adherence message after 48 hours of not using the GlowCaps

Electronic Pill Bottle tracking; Adherence Messaging

干预措施: Electronic Pill Bottle tracking (Behavioral)

Feedback group

Experimental

This arm will use GlowCaps to have their adherence tracked with the following modifications:

Arm 2. Feedback group participants will receive an adherence message after 48 hours of not using the GlowCaps

Electronic Pill Bottle tracking; Adherence Messaging

干预措施: Adherence Messaging (Behavioral)

Adherence partner group

Experimental

This arm will use GlowCaps to have their adherence tracked with the following modifications:

Arm 3. Adherence partner group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient

Electronic Pill Bottle tracking; Social Influence

干预措施: Electronic Pill Bottle tracking (Behavioral)

Adherence partner group

Experimental

This arm will use GlowCaps to have their adherence tracked with the following modifications:

Arm 3. Adherence partner group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient

Electronic Pill Bottle tracking; Social Influence

干预措施: Social Influence (Behavioral)

Adherence partner along with feedback

Experimental

This arm will use GlowCaps to have their adherence tracked with the following modifications:

Arm 4. Adherence partner along with feedback group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient, both the patient and partner will receive a message after 48 hours of not using the GlowCaps

Electronic Pill Bottle tracking; Adherence Messaging; Social Influence

干预措施: Electronic Pill Bottle tracking (Behavioral)

Adherence partner along with feedback

Experimental

This arm will use GlowCaps to have their adherence tracked with the following modifications:

Arm 4. Adherence partner along with feedback group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient, both the patient and partner will receive a message after 48 hours of not using the GlowCaps

Electronic Pill Bottle tracking; Adherence Messaging; Social Influence

干预措施: Adherence Messaging (Behavioral)

Adherence partner along with feedback

Experimental

This arm will use GlowCaps to have their adherence tracked with the following modifications:

Arm 4. Adherence partner along with feedback group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient, both the patient and partner will receive a message after 48 hours of not using the GlowCaps

Electronic Pill Bottle tracking; Adherence Messaging; Social Influence

干预措施: Social Influence (Behavioral)

结局指标

主要结局

Glowcap bottle openings/Medication Adherence

时间窗: 6 months

Primary outcome will measure the the number of days the GlowCap pill bottle is opened at least 1 time over the 6 month enrollment period, to be measured at 6 months after enrollment for each participant. Medication adherence for this study is considered to be at least 1 registered GlowCap opening for each day enrolled on the study. (N days at least 1 opening/180 days = Medication Adherence %)

次要结局

  • Patient Claims records - this will be a composite outcome measure assessing frequency of hospitalization(18 months)
  • Patient pharmacy benefits-this will be a composite outcome measure assessing MPR(18 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验